Switch theme
Sign up to access all valuation multiples
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
1993
338
LTM Revenue $394M
LTM EBITDA $86.9M
$6.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TG Therapeutics has a last 12-month revenue of $394M and a last 12-month EBITDA of $86.9M.
In the most recent fiscal year, TG Therapeutics achieved revenue of $329M and an EBITDA of $49.9M.
TG Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TG Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $234M | $329M | XXX | XXX | XXX |
| Gross Profit | $2.5M | $220M | XXX | XXX | XXX |
| Gross Margin | 1% | 67% | XXX | XXX | XXX |
| EBITDA | $26.1M | $49.9M | XXX | XXX | XXX |
| EBITDA Margin | 11% | 15% | XXX | XXX | XXX |
| Net Profit | -$198M | $12.7M | XXX | XXX | XXX |
| Net Margin | -85% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | $7.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TG Therapeutics's stock price is $38.
TG Therapeutics has current market cap of $6.0B, and EV of $6.0B.
See TG Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.0B | $6.0B | XXX | XXX | XXX | XXX | $0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TG Therapeutics has market cap of $6.0B and EV of $6.0B.
TG Therapeutics's trades at 15.2x LTM EV/Revenue multiple, and 68.8x LTM EBITDA.
Analysts estimate TG Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TG Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.0B | XXX | XXX | XXX |
| EV/Revenue | 18.2x | XXX | XXX | XXX |
| EV/EBITDA | 119.8x | XXX | XXX | XXX |
| P/E | 258.0x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | -147.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTG Therapeutics's NTM/LTM revenue growth is 57%
TG Therapeutics's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, TG Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TG Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TG Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 91% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 73% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 76% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TG Therapeutics acquired XXX companies to date.
Last acquisition by TG Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . TG Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TG Therapeutics founded? | TG Therapeutics was founded in 1993. |
| Where is TG Therapeutics headquartered? | TG Therapeutics is headquartered in United States of America. |
| How many employees does TG Therapeutics have? | As of today, TG Therapeutics has 338 employees. |
| Who is the CEO of TG Therapeutics? | TG Therapeutics's CEO is Mr. Michael S. Weiss. |
| Is TG Therapeutics publicy listed? | Yes, TG Therapeutics is a public company listed on NAS. |
| What is the stock symbol of TG Therapeutics? | TG Therapeutics trades under TGTX ticker. |
| When did TG Therapeutics go public? | TG Therapeutics went public in 1995. |
| Who are competitors of TG Therapeutics? | Similar companies to TG Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TG Therapeutics? | TG Therapeutics's current market cap is $6.0B |
| What is the current revenue of TG Therapeutics? | TG Therapeutics's last 12-month revenue is $394M. |
| What is the current EBITDA of TG Therapeutics? | TG Therapeutics's last 12-month EBITDA is $86.9M. |
| What is the current EV/Revenue multiple of TG Therapeutics? | Current revenue multiple of TG Therapeutics is 15.2x. |
| What is the current EV/EBITDA multiple of TG Therapeutics? | Current EBITDA multiple of TG Therapeutics is 68.8x. |
| What is the current revenue growth of TG Therapeutics? | TG Therapeutics revenue growth between 2023 and 2024 was 41%. |
| Is TG Therapeutics profitable? | Yes, TG Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
